NITE - ナイトスタ―・セラピュ―ティクス (Nightstar Therapeutics plc) ナイトスタ―・セラピュ―ティクス

 NITEのチャート


 NITEの企業情報

symbol NITE
会社名 Nightstar Therapeutics PLC (ナイトスタ―・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Nightstar Therapeutics PLC formerly Nightstar Therapeutics Limited is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Company’s lead product candidate NSR-REP1 for the treatment of choroideremia or CHM is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate NSR-RPGR for the treatment of X-linked retinitis pigmentosa or XLRP. The Company’s third product candidate NSR-BEST1 is in preclinical development for the treatment of Best vitelliform macular dystrophy or Best disease.   ナイトスタ―・セラピュ―ティクスはイギリス医薬品企業。臨床段階で、遺伝性網膜疾患に対する遺伝子治療の開発・商業化に従事する。承認された治療法がなくし、一度の遺伝子治療で網膜疾患の進行を改変または停止するように設計された独自のパイプラインを開発する。同社の医薬品候補「NSR-REP1」はチロイド血症やCHMの治療を行う。本社所在地はロンドン。   Nightstar Therapeutics plc is a clinical-stage gene therapy holding company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy. The company was founded by Robert MacLaren on July 6, 2017 and is headquartered in London, the United Kingdom.
本社所在地 215 Euston Road London NW1 2BE GBR
代表者氏名
代表者役職名
電話番号 +44 20-7611-2077
設立年月日 42917
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 27人
url www.nightstartx.com
nasdaq_url https://www.nasdaq.com/symbol/nite
adr_tso 6398757
EBITDA EBITDA(百万ドル) -37.05200
終値(lastsale) 16.96
時価総額(marketcap) 108522918.72
時価総額 時価総額(百万ドル) 461.03510
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 349.67410
当期純利益 当期純利益(百万ドル) -44.44700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Nightstar Therapeutics PLC revenues was not reported. Net loss increased from $7.7M to $22.5M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.27 to -$0.80.

 NITEのテクニカル分析


 NITEのニュース

   Uber Time (Stocks To Watch Podcast)  2019/05/05 12:00:21 Seeking Alpha
   Market At New Highs, But Healthcare And Biotechs Feel The Heat  2019/04/29 17:22:32 Seeking Alpha
   Merger Arbitrage Mondays - April 22, 2019  2019/04/22 10:20:43 Seeking Alpha
   6 Gene Therapy M&A Targets On The Radar  2019/03/27 16:45:40 Benzinga
Biogen Inc (NASDAQ: BIIB ) to acquire gene therapy company Nightstar Therapeutics PLC (NASDAQ: NITE ). Roche Holdings AG Basel ADR (OTC: RHHBY ) agrees to buy Spark Therapeutics Inc (NASDAQ: ONCE ). Sarepta Therapeutics Inc (NASDAQ: SRPT ) exercises option to buy Myonexus Therapeutics for $165 million, acquiring five gene therapy candidates to treat limb-girdle muscular dystrophy. Johnson & Johnson (NYSE: JNJ )'s Janssen unit signs a licensing deal with gene therapy company MeiraGTx Holdings PLC (NASDAQ: MGTX ) for developing a portfolio of drugs for inherited retinal disease. Incidentally, J&J's investment arm JJDC buys $40 million of MeiraGTx shares in a $80 million private placement that closed March 1. Pfizer Inc. (NYSE: PFE ) picks up a 15-percent stake in French gene therapy company Vivet Therapeutics, along with an option to fully acquire the company. Gene therapy M&A headlines have taken the spotlight this year, following up on two major gene therapy deals announced in 2018: Celgene Corporation (NASDAQ: CELG )'s $9-billion purchase of Juno and Novartis AG (NYSE: NVS )'s acquisition of AveXis for $8.7 billion.
   Biogen Is Next In Line With Purchase Of Gene Therapy Biotech  2019/03/12 18:38:32 Seeking Alpha
   Uber Time (Stocks To Watch Podcast)  2019/05/05 12:00:21 Seeking Alpha
   Market At New Highs, But Healthcare And Biotechs Feel The Heat  2019/04/29 17:22:32 Seeking Alpha
   Merger Arbitrage Mondays - April 22, 2019  2019/04/22 10:20:43 Seeking Alpha
   6 Gene Therapy M&A Targets On The Radar  2019/03/27 16:45:40 Benzinga
Biogen Inc (NASDAQ: BIIB ) to acquire gene therapy company Nightstar Therapeutics PLC (NASDAQ: NITE ). Roche Holdings AG Basel ADR (OTC: RHHBY ) agrees to buy Spark Therapeutics Inc (NASDAQ: ONCE ). Sarepta Therapeutics Inc (NASDAQ: SRPT ) exercises option to buy Myonexus Therapeutics for $165 million, acquiring five gene therapy candidates to treat limb-girdle muscular dystrophy. Johnson & Johnson (NYSE: JNJ )'s Janssen unit signs a licensing deal with gene therapy company MeiraGTx Holdings PLC (NASDAQ: MGTX ) for developing a portfolio of drugs for inherited retinal disease. Incidentally, J&J's investment arm JJDC buys $40 million of MeiraGTx shares in a $80 million private placement that closed March 1. Pfizer Inc. (NYSE: PFE ) picks up a 15-percent stake in French gene therapy company Vivet Therapeutics, along with an option to fully acquire the company. Gene therapy M&A headlines have taken the spotlight this year, following up on two major gene therapy deals announced in 2018: Celgene Corporation (NASDAQ: CELG )'s $9-billion purchase of Juno and Novartis AG (NYSE: NVS )'s acquisition of AveXis for $8.7 billion.
   Biogen Is Next In Line With Purchase Of Gene Therapy Biotech  2019/03/12 18:38:32 Seeking Alpha
   Uber Time (Stocks To Watch Podcast)  2019/05/05 12:00:21 Seeking Alpha
   Market At New Highs, But Healthcare And Biotechs Feel The Heat  2019/04/29 17:22:32 Seeking Alpha
   Merger Arbitrage Mondays - April 22, 2019  2019/04/22 10:20:43 Seeking Alpha
   6 Gene Therapy M&A Targets On The Radar  2019/03/27 16:45:40 Benzinga
Biogen Inc (NASDAQ: BIIB ) to acquire gene therapy company Nightstar Therapeutics PLC (NASDAQ: NITE ). Roche Holdings AG Basel ADR (OTC: RHHBY ) agrees to buy Spark Therapeutics Inc (NASDAQ: ONCE ). Sarepta Therapeutics Inc (NASDAQ: SRPT ) exercises option to buy Myonexus Therapeutics for $165 million, acquiring five gene therapy candidates to treat limb-girdle muscular dystrophy. Johnson & Johnson (NYSE: JNJ )'s Janssen unit signs a licensing deal with gene therapy company MeiraGTx Holdings PLC (NASDAQ: MGTX ) for developing a portfolio of drugs for inherited retinal disease. Incidentally, J&J's investment arm JJDC buys $40 million of MeiraGTx shares in a $80 million private placement that closed March 1. Pfizer Inc. (NYSE: PFE ) picks up a 15-percent stake in French gene therapy company Vivet Therapeutics, along with an option to fully acquire the company. Gene therapy M&A headlines have taken the spotlight this year, following up on two major gene therapy deals announced in 2018: Celgene Corporation (NASDAQ: CELG )'s $9-billion purchase of Juno and Novartis AG (NYSE: NVS )'s acquisition of AveXis for $8.7 billion.
   Biogen Is Next In Line With Purchase Of Gene Therapy Biotech  2019/03/12 18:38:32 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ナイトスタ―・セラピュ―ティクス NITE Nightstar Therapeutics plc)

 twitter  (公式ツイッターやCEOツイッターなど)